ZA932491B - Vaccines - Google Patents

Vaccines

Info

Publication number
ZA932491B
ZA932491B ZA932491A ZA932491A ZA932491B ZA 932491 B ZA932491 B ZA 932491B ZA 932491 A ZA932491 A ZA 932491A ZA 932491 A ZA932491 A ZA 932491A ZA 932491 B ZA932491 B ZA 932491B
Authority
ZA
South Africa
Prior art keywords
pct
vesicles
sec
date
date jan
Prior art date
Application number
ZA932491A
Other languages
English (en)
Inventor
James Alexander
James Macdonald Brewer
Original Assignee
Proteur Molecular Design Limit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteur Molecular Design Limit filed Critical Proteur Molecular Design Limit
Publication of ZA932491B publication Critical patent/ZA932491B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA932491A 1992-04-07 1993-04-07 Vaccines ZA932491B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207731A GB9207731D0 (en) 1992-04-07 1992-04-07 Improvements in or relating to vaccines

Publications (1)

Publication Number Publication Date
ZA932491B true ZA932491B (en) 1993-11-02

Family

ID=10713695

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932491A ZA932491B (en) 1992-04-07 1993-04-07 Vaccines

Country Status (16)

Country Link
US (1) US5679355A (no)
EP (1) EP0634937B1 (no)
JP (1) JP2690620B2 (no)
KR (1) KR950700758A (no)
CN (1) CN1085449A (no)
AT (1) ATE158185T1 (no)
AU (1) AU3899793A (no)
CA (1) CA2132547C (no)
DE (1) DE69314020T2 (no)
FI (1) FI944676A (no)
GB (1) GB9207731D0 (no)
HU (1) HUT69935A (no)
NO (1) NO943739D0 (no)
NZ (1) NZ251402A (no)
WO (1) WO1993019781A1 (no)
ZA (1) ZA932491B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AU680996B2 (en) * 1993-12-17 1997-08-14 Novavax, Inc. Method of transmitting a biologically active material to a cell
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9515868D0 (en) * 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
JP2002511423A (ja) * 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
FI112825B (fi) * 2001-07-11 2004-01-15 Antti Nissinen Menetelmä alkoholinkulutuksen osoittamiseksi, menetelmässä käytettäviä välineitä sekä niiden valmistus
CN1665487A (zh) * 2002-07-03 2005-09-07 埃弗顿有限公司 脂质体疫苗
WO2004045583A1 (ja) * 2002-11-15 2004-06-03 Nipro Corporation リポソーム
FR2850872A1 (fr) * 2003-02-12 2004-08-13 Ethypharm Sa Composition vaccinale destinee a induire une reponse immunitaire contre le virus responsable du sida
AU2004271893B2 (en) 2003-08-28 2010-07-29 Becton, Dickinson And Company Intradermal injection device
CN101313216A (zh) * 2005-09-22 2008-11-26 普洛茨股份有限公司 酵母突变体中产生的糖基化多肽及其使用方法
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
EP3173125B1 (en) 2008-07-30 2019-03-27 Ecole Polytechnique Fédérale de Lausanne Apparatus for optimized stimulation of a neurological target
EP2382008B1 (en) 2008-11-12 2015-04-29 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2782710C (en) 2009-12-01 2019-01-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device and methods of making and using the same
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP6077858B2 (ja) * 2011-01-07 2017-02-08 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
US9309307B2 (en) * 2011-01-07 2016-04-12 Seiko Epson Corporation Antibody against amyloid precursor protein signal peptide
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
EP2663288B1 (en) * 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20150079077A1 (en) * 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
WO2015173787A1 (en) 2014-05-16 2015-11-19 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9925376B2 (en) 2014-08-27 2018-03-27 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2597346B1 (fr) * 1986-04-22 1989-08-18 Oreal Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
DE3867635D1 (de) * 1987-03-13 1992-02-20 Micro Vesicular Systems Lipidversikel aus grenzflaechenaktiven stoffen und sterolen.
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
LU87449A1 (fr) * 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
AU654858B2 (en) * 1991-03-28 1994-11-24 Novavax, Inc. Lipid vesicle containing water-in-oil emulsions

Also Published As

Publication number Publication date
JPH07505389A (ja) 1995-06-15
ATE158185T1 (de) 1997-10-15
KR950700758A (ko) 1995-02-20
GB9207731D0 (en) 1992-05-27
FI944676A0 (fi) 1994-10-06
HUT69935A (en) 1995-09-28
DE69314020D1 (de) 1997-10-23
CA2132547C (en) 2000-06-06
FI944676A (fi) 1994-10-06
WO1993019781A1 (en) 1993-10-14
JP2690620B2 (ja) 1997-12-10
CA2132547A1 (en) 1993-10-14
DE69314020T2 (de) 1998-08-06
US5679355A (en) 1997-10-21
NO943739L (no) 1994-10-05
HU9402904D0 (en) 1995-01-30
EP0634937B1 (en) 1997-09-17
EP0634937A1 (en) 1995-01-25
NZ251402A (en) 1996-10-28
NO943739D0 (no) 1994-10-05
AU3899793A (en) 1993-11-08
CN1085449A (zh) 1994-04-20

Similar Documents

Publication Publication Date Title
ZA932491B (en) Vaccines
NO954786D0 (no) Hjelpestoffer for vaksiner mot åndedretts-syncytalvirus
MY134811A (en) A vaccine composition comprising an antigen, a saponin and a sterol
DK0760649T3 (da) Præparater af fluticason-propionat
AU2001295673A1 (en) Vaccine composition
IL142948A0 (en) Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
DK0745387T3 (da) Adjuvanser til virale vacciner
ATE153071T1 (de) Neue proteinhaltige partikeln
CA2086094A1 (en) Vaccine compositions containing liposomes
HU9601462D0 (en) Adjuvants for viral vaccines
AU5646101A (en) Immunotherapeutic methods and compositions
DE69420970D1 (de) Impfstoff zubereitungen
DE69322960D1 (de) Empfängnisverhütender impfstoff
Zhang Study of protective effect of outer membrane proteins of Vibrio cholerae with monoclonal antibodies.